Brena Dara, Huang Ming-Bo, Bond Vincent
Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, United States.
Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, United States.
Transl Oncol. 2022 Jan;15(1):101286. doi: 10.1016/j.tranon.2021.101286. Epub 2021 Nov 25.
Breast cancer metastatic progression to critical secondary sites is the second leading cause of cancer-related mortality in women. While existing therapies are highly effective in combating primary tumors, metastatic disease is generally deemed incurable with a median survival of only 2, 3 years. Extensive efforts have focused on identifying metastatic contributory targets for therapeutic antagonism and prevention to improve patient survivability. Excessive breast cancer release of extracellular vesicles (EVs), whose contents stimulate a metastatic phenotype, represents a promising target. Complex breast cancer intercellular communication networks are based on EV transport and transference of molecular information is in bulk resulting in complete reprogramming events within recipient cells. Other breast cancer cells can acquire aggressive phenotypes, endothelial cells can be induced to undergo tubule formation, and immune cells can be neutralized. Recent advancements continue to implicate the critical role EVs play in cultivating a tumor microenvironment tailored to cancer proliferation, metastasis, immune evasion, and conference of drug resistance. This literature review serves to frame the role of EV transport in breast cancer progression and metastasis. The following five sections will be addressed: (1) Intercellular communication in developing a tumor microenvironment & pre-metastatic niche. (2) Induction of the epithelial-to-mesenchymal transition (EMT). (3). Immune suppression & evasion. (4) Transmission of drug resistance mechanisms. (5) Precision medicine: clinical applications of EVs.
乳腺癌转移至关键继发部位是女性癌症相关死亡的第二大主要原因。虽然现有疗法在对抗原发性肿瘤方面非常有效,但转移性疾病通常被认为无法治愈,中位生存期仅为2至3年。人们已付出大量努力,致力于确定可用于治疗性拮抗和预防的转移性相关靶点,以提高患者的生存率。乳腺癌过度释放细胞外囊泡(EVs),其内容物会刺激转移表型,这是一个很有前景的靶点。复杂的乳腺癌细胞间通讯网络基于EVs的转运,分子信息的大量转移会导致受体细胞内发生完全的重编程事件。其他乳腺癌细胞可获得侵袭性表型,内皮细胞可被诱导形成小管,免疫细胞可被中和。最近的进展继续表明EVs在营造有利于癌症增殖、转移、免疫逃逸和产生耐药性的肿瘤微环境中起着关键作用。这篇文献综述旨在阐述EVs转运在乳腺癌进展和转移中的作用。将探讨以下五个方面:(1)肿瘤微环境和前转移生态位形成中的细胞间通讯。(2)上皮-间质转化(EMT)的诱导。(3)免疫抑制与逃逸。(4)耐药机制的传递。(5)精准医学:EVs的临床应用。